New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 13, 2013
17:37 EDTNSTGNanoString: PAM50-based Prosigna Assay may help identify at risk patients
NanoString Technologies announced new results from a combined analysis of the Austrian Breast & Colorectal Cancer Study Group 8 and Trans-Arimidex, Tamoxifen, Alone or in Combination studies. These results, which evaluated samples from 2,137 patients, suggest that the PAM50-based Prosign Breast Cancer Prognostic Gene Signature Assay may help identify women with late distant recurrence after five years of endocrine treatment. Using the Prosigna Assay, the study investigators classified patient tumors by subtype and found that patients with Luminal B subtype have three times higher risk of late distant recurrence than patients with Luminal A subtype tumors. Results were presented today at the 2013 San Antonio Breast Cancer Symposium. “Women with estrogen receptor positive breast cancer have a high risk of recurrence for at least 10 years after diagnosis, even after five years of endocrine therapy. To provide better care for these women, more informative biomarkers are needed to help predict risk of late recurrence,” said Ivana Sestak, PhD, The Centre for Cancer Prevention, Wolfson Institute of Prevention Medicine, Queen Mary University and lead investigator of this study. “As a result of our study, we determined that the risk of recurrence score, or ROR score generated by the PAM50-powered Prosigna Assay provides significant prognostic information that may be used by oncologists and pathologists to help guide care decisions for postmenopausal women with hormone receptor-positive breast cancer who may be at higher risk of late distant recurrence of disease in the absence of additional treatment.”
News For NSTG From The Last 14 Days
Check below for free stories on NSTG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for NSTG

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use